LOWELL, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2024 financial results prior to the market open on Friday, August 2, 2024. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mis ...

In conjunction with the release, the Company's management team will host a webcast conference call at 8:30 a.m. ET on Friday, August 2, 2024. The live webcast will be accessible on the Company's website here and will be available for replay for one year from the webcast date. Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccine ...

Table of Contents For the transition period from ________________ to ________________ Commission File Number: 001-40592 ________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or o TRANSITION REPORT PURSUANT TO SECTI ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Robert Spignesi - President and CEO Sean Wirtjes - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Steven Mah - TD Cowen Operator Thank you for standing by. My name is John, and I will be your conference operator for today. All lines have been placed on mute to prevent any backgro ...

Exhibit 99.1 Rapid Micro Biosystems Reports First Quarter 2024 Financial Results Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023 Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023 LOWELL, Mass., May 3, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the "Company"), an innovative life sciences technology company providing mission crit ...

Table of Contents FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-8121647 (State or other jurisdiction of incorporation or organization) (I.R.S. Emplo ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q4 2023 Earnings Conference Call March 1, 2024 8:30 AM ET Company Participants Michael Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Robert Spignesi - President and CEO Sean Wirtjes - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Steven Mah - TD Cowen Operator Ladies and gentlemen, thank you for standing by. My name is Desiree [ph], and I will be your conference operator today. At this time, I would like ...

兩間公司共同致力創新品質控制流程，以應對規模、數據完整性和加快上市時間等生物製造挑戰羅威爾，麻薩諸塞州, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID)（以下簡稱「公司」）是一間創新生命科學技術公司，提供關鍵任務自動化解決方案，以促進醫療保健產品的高效生產和快速、安全發布。該公司今日宣布 Samsung Biologics (KRX: 207940.KS) 選擇了 Growth Direct® 平台來自動化其微生物品質控制流程，以提高效率、更穩健的數據完整性和可擴展的品質控制操作。 Rapid Micro Biosystems 董事長兼行政總裁 Robert Spignesi 表示：「Samsung Biologics 作為全球領先的合約開發和製造組織 (CDMO)，展示了對生物製藥生產自動化和品質管理的堅定承諾。」「Growth Direct® 提高了品質控制微生物實驗室的營運效率和數據完整性，我們很榮幸能與 Samsung Biologics 合作。」 很多全球製藥商依靠 Growth Direct ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File N ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q3 2023 Earnings Call Transcript November 3, 2023 8:30 AM ET Company Participants Michael Beaulieu - Vice President of Investor Relations Robert Spignesi - CEO, President and Director Sean Wirtjes - Chief Financial Officer Conference Call Participants Daniel Arias - Stifel Steven Mah - TD Cowen Operator Thank you for holding, and welcome, everyone, to the Rapid Micro Biosystems' Third Quarter 2023 Earnings Call. All lines have been placed on mute to prevent any bac ...